News
TOP NEWS
02/06/2024
02/06/2024
Capturing the value of environmental impact and sustainability in pharmaceutical health technology assessment
The healthcare sector is responsible for a substantial share of global carbon emissions, contributing approximately 4-5% of total global greenhouse gas emissions.
Read now
10/24/2023
French HTA assessment in cases of significant uncertainty: Added value and reassessment
In October 2018, the French HTA body (Transparency Committee, TC of the HAS) introduced the concept of clinical benefit (CB, Service Médical Rendu or SMR) in cases of significant uncertainty, particularly due to early or limited data.
06/02/2023
What is the Future of Rare Disease Research and Development in the EU?
Rare diseases are a major public health issue in the European Union (EU), affecting an estimated 30 million people, or between 6% and 8% of the population. (1)
02/22/2023
More price negotiations on new expensive drugs in the Netherlands
On the 24th of January 2023, the Dutch Minister of Health, Welfare and Sport Ernst Kuipers has decided to adapt the rules for admission of expensive (intramural) medicines to the basic health insurance package as from 1st July 2023. He is doing this by tightening the so-called lock criteria.
